---
title: "Praxis Precision Medicines, Inc. (PRAX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRAX.US.md"
symbol: "PRAX.US"
name: "Praxis Precision Medicines, Inc."
industry: "Biotechnology"
datetime: "2026-06-10T12:59:23.477Z"
locales:
  - [en](https://longbridge.com/en/quote/PRAX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRAX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRAX.US.md)
---

# Praxis Precision Medicines, Inc. (PRAX.US)

## Company Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [raxismedicines.com](https://raxismedicines.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -21.37 | 505 | - | - | - |
| PB | 4.95 | 327 | 18.79 | 9.60 | 2.48 |
| PS (TTM) | 1246.19 | - | 1246.19 | 876.51 | 129.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-08T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 13 | 76% |
| Overweight | 2 | 12% |
| Hold | 1 | 6% |
| Sell | 1 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 250.33 |
| Highest Target | 1245.00 |
| Lowest Target | 166.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PRAX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PRAX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PRAX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PRAX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**